The COVID-19 pandemic was and still is a global burden with more than 178,000,000 cases reported so far. Although it mainly affects respiratory organs, COVID-19 has many extrapulmonary manifestations, including, among other things, liver injury. Many hypotheses have been proposed to explain direct and indirect impacts of the SARS-CoV-2 virus on the liver. Studies have shown that around 15–30% of patients with COVID-19 have underlying liver disease, and 20–35% of patients with COVID-19 had altered liver enzymes at admission. One of the hypotheses is reactivation of an underlying liver disease, such as non-alcoholic fatty liver disease (NAFLD). Some studies have shown that NAFLD is associated with severe COVID-19 and poor outcome; nevertheless, other studies showed no significant difference between groups in comparing complications and clinical outcomes. Patients with NAFLD may suffer severe COVID-19 due to other comorbidities, especially cardiovascular diseases. The link between NAFLD and COVID-19 is not clear yet, and further studies and research are needed.
【저자키워드】 COVID-19, metabolic syndrome, Non-alcoholic fatty liver disease, Liver injury, metabolic-associated fatty liver disease, 【초록키워드】 severe COVID-19, COVID-19 pandemic, Comorbidities, cardiovascular diseases, clinical outcomes, Impact, Research, Complication, Manifestations, Fatty liver, group, disease, Admission, liver, Liver disease, liver enzyme, NAFLD, no significant difference, organs, Affect, shown, reported, explain, hypothese, patients with COVID-19, Patients with NAFLD, the SARS-CoV-2 virus, 【제목키워드】 time,